Al-Shahi Salman R et al. - Through REstart or STop Antithrombotics Randomised Trial (RESTART, a prospective, randomized, open-label, blinded endpoint, parallel-group trial) at 122 hospitals in the UK on 537 individuals, researchers intended to measure the relative and absolute impacts of antiplatelet therapy on recurrent intracerebral hemorrhage and to assess if this risk could surpass any decrease of occlusive vascular events. Two hundred and sixty-eight participants were randomized to begin and 269 to not begin antiplatelet therapy. Intracerebral hemorrhage recurrence was observed in 12 out of 268 participants allotted to antiplatelet therapy vs 23 of 268 participants designated to not begin antiplatelet therapy. Eight patients who took antiplatelet therapy experienced major hemorrhagic events vs 25 members allotted to not take antiplatelet therapy; 39 individuals categorized to take antiplatelet therapy experienced major occlusive vascular events vs 38 allocated to not take antiplatelet therapy. For the prevention of occlusive vascular disease after developing intracerebral hemorrhage, a very moderate elevation in the risk of recurrent intracerebral hemorrhage with antiplatelet therapy for patients on antithrombotic therapy was observed.